Literature DB >> 25275853

Reliability and validity of the Symptoms of Depression Questionnaire (SDQ).

Paola Pedrelli1, Mark A Blais1, Jonathan E Alpert2, Richard C Shelton3, Rosemary S W Walker2, Maurizio Fava4.   

Abstract

Current measures for major depressive disorder focus primarily on the assessment of depressive symptoms, while often omitting other common features. However, the presence of comorbid features in the anxiety spectrum influences outcome and may effect treatment. More comprehensive measures of depression are needed that include the assessment of symptoms in the anxiety-depression spectrum. This study examines the reliability and validity of the Symptoms of Depression Questionnaire (SDQ), which assesses irritability, anger attacks, and anxiety symptoms together with the commonly considered symptoms of depression. Analysis of the factor structure of the SDQ identified 5 subscales, including one in the anxiety-depression spectrum, with adequate internal consistency and concurrent validity. The SDQ may be a valuable new tool to better characterize depression and identify and administer more targeted interventions.

Entities:  

Mesh:

Year:  2014        PMID: 25275853      PMCID: PMC4524555          DOI: 10.1017/S1092852914000406

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  23 in total

1.  SPSS and SAS programs for determining the number of components using parallel analysis and velicer's MAP test.

Authors:  B P O'Connor
Journal:  Behav Res Methods Instrum Comput       Date:  2000-08

2.  Psychometric properties and diagnostic utility of the Beck Anxiety Inventory and the State-Trait Anxiety Inventory with older adult psychiatric outpatients.

Authors:  R I Kabacoff; D L Segal; M Hersen; V B Van Hasselt
Journal:  J Anxiety Disord       Date:  1997 Jan-Feb

3.  A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia.

Authors:  M Fava; A A Nierenberg; F M Quitkin; S Zisook; T Pearlstein; A Stone; J F Rosenbaum
Journal:  Psychopharmacol Bull       Date:  1997

4.  An inventory for measuring clinical anxiety: psychometric properties.

Authors:  A T Beck; N Epstein; G Brown; R A Steer
Journal:  J Consult Clin Psychol       Date:  1988-12

5.  The Suicidal Behaviors Questionnaire-Revised (SBQ-R): validation with clinical and nonclinical samples.

Authors:  A Osman; C L Bagge; P M Gutierrez; L C Konick; B A Kopper; F X Barrios
Journal:  Assessment       Date:  2001-12

6.  The structure and stability of common mental disorders: the NEMESIS study.

Authors:  W A Vollebergh; J Iedema; R V Bijl; R de Graaf; F Smit; J Ormel
Journal:  Arch Gen Psychiatry       Date:  2001-06

7.  The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women.

Authors:  Kenneth S Kendler; Carol A Prescott; John Myers; Michael C Neale
Journal:  Arch Gen Psychiatry       Date:  2003-09

8.  The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.

Authors:  A John Rush; Madhukar H Trivedi; Hicham M Ibrahim; Thomas J Carmody; Bruce Arnow; Daniel N Klein; John C Markowitz; Philip T Ninan; Susan Kornstein; Rachel Manber; Michael E Thase; James H Kocsis; Martin B Keller
Journal:  Biol Psychiatry       Date:  2003-09-01       Impact factor: 13.382

9.  Mixed anxiety-depression in a primary-care clinic.

Authors:  M B Stein; P Kirk; V Prabhu; M Grott; M Terepa
Journal:  J Affect Disord       Date:  1995-05-17       Impact factor: 4.839

Review 10.  Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV.

Authors:  Rudolf Uher; Jennifer L Payne; Barbara Pavlova; Roy H Perlis
Journal:  Depress Anxiety       Date:  2013-11-22       Impact factor: 6.505

View more
  11 in total

1.  Effects of Open-Label, Adjunctive Ganaxolone on Persistent Depression Despite Adequate Antidepressant Treatment in Postmenopausal Women: A Pilot Study.

Authors:  Laura E Dichtel; Maren Nyer; David Mischoulon; Maurizio Fava; Karen K Miller; Christina Dording; Lauren B Fisher; Cristina Cusin; Benjamin G Shapero; Paola Pedrelli; Allison S Kimball; Elizabeth M Rao
Journal:  J Clin Psychiatry       Date:  2020-06-09       Impact factor: 4.384

2.  Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD).

Authors:  Maurizio Fava; Marlene P Freeman; Martina Flynn; Bettina B Hoeppner; Richard Shelton; Dan V Iosifescu; James W Murrough; David Mischoulon; Cristina Cusin; Mark Rapaport; Boadie W Dunlop; Madhukar H Trivedi; Manish Jha; Gerard Sanacora; Gretchen Hermes; George I Papakostas
Journal:  Brain Stimul       Date:  2017-09-23       Impact factor: 8.955

3.  A longitudinal study of women's depression symptom profiles during and after the postpartum phase.

Authors:  Molly Fox; Curt A Sandman; Elysia Poggi Davis; Laura M Glynn
Journal:  Depress Anxiety       Date:  2018-02-02       Impact factor: 6.505

4.  The clinical characterization of the adult patient with depression aimed at personalization of management.

Authors:  Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

5.  Open-label placebo for major depressive disorder: a pilot randomized controlled trial.

Authors:  John M Kelley; Ted J Kaptchuk; Cristina Cusin; Samuel Lipkin; Maurizio Fava
Journal:  Psychother Psychosom       Date:  2012-08-01       Impact factor: 17.659

Review 6.  Depression sum-scores don't add up: why analyzing specific depression symptoms is essential.

Authors:  Eiko I Fried; Randolph M Nesse
Journal:  BMC Med       Date:  2015-04-06       Impact factor: 8.775

7.  A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.

Authors:  G I Papakostas; K Johe; H Hand; A Drouillard; P Russo; G Kay; R Kashambwa; B Hoeppner; M Flynn; A Yeung; M A Martinson; M Fava
Journal:  Mol Psychiatry       Date:  2019-01-09       Impact factor: 15.992

8.  Usability of a Mobile App for Real-Time Assessment of Fatigue and Related Symptoms in Patients With Multiple Sclerosis: Observational Study.

Authors:  Miklos Palotai; Max Wallack; Gergo Kujbus; Adam Dalnoki; Charles Guttmann
Journal:  JMIR Mhealth Uhealth       Date:  2021-04-16       Impact factor: 4.773

9.  A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.

Authors:  M Fava; K Johe; L Ereshefsky; L G Gertsik; B A English; J A Bilello; L M Thurmond; J Johnstone; B C Dickerson; N Makris; B B Hoeppner; M Flynn; D Mischoulon; G Kinrys; M P Freeman
Journal:  Mol Psychiatry       Date:  2015-12-08       Impact factor: 15.992

10.  Protocol for a randomized controlled trial examining multilevel prediction of response to behavioral activation and exposure-based therapy for generalized anxiety disorder.

Authors:  J Santiago; E Akeman; N Kirlic; A N Clausen; K T Cosgrove; T J McDermott; B Mathis; M Paulus; M G Craske; J Abelson; C Martell; K Wolitzky-Taylor; J Bodurka; W K Thompson; Robin L Aupperle
Journal:  Trials       Date:  2020-01-06       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.